Session » SLE – Diagnosis, Manifestations, & Outcomes Poster III
- 10:30AM-12:30PM
-
Abstract Number: 2401
A Novel Modeling Approach to Elucidate the Role of Autoantibodies in Complement Activation in SLE
- 10:30AM-12:30PM
-
Abstract Number: 2410
A Novel Treatment Response Measure for SLE Clinical Trials (TRM-SLE): Selection of Domains and Candidate Measures
- 10:30AM-12:30PM
-
Abstract Number: 2414
A Retrospective Comparative Analysis of Cardiovascular Risk Factors, Atherosclerotic Cardiovascular Disease and Statin Use as Secondary Prevention in a Cohort of Patients with Systemic Lupus Erythematosus versus Without Rheumatological Disease from a Single-Center Patient Registry
- 10:30AM-12:30PM
-
Abstract Number: 2409
Adherence to EULAR Recommendations and Sub Optimal Management of Systemic Lupus Erythematosus in a Network of Community-Based Rheumatology Practices in the United States
- 10:30AM-12:30PM
-
Abstract Number: 2390
Anti-Sm Antibody Titers Vary During SLE Disease Course
- 10:30AM-12:30PM
-
Abstract Number: 2411
Attainment of Complete Renal Response in Patients with Active Lupus Nephritis: A Multi-Center Cohort Study
- 10:30AM-12:30PM
-
Abstract Number: 2402
Belimumab Reduces Disease Flares versus Placebo in Adults with Early Active Systemic Lupus Erythematosus: Results of a Large Integrated Analysis
- 10:30AM-12:30PM
-
Abstract Number: 2387
Biomarkers of Lupus Nephritis Are Less Predictive in APOL1 High Risk Genotype Lupus
- 10:30AM-12:30PM
-
Abstract Number: 2420
Blood Transcriptome Analysis Reveals Enhanced B Cell and Complement Cascade Signatures in Patients with Major Neuropsychiatric Systemic Lupus Erythematosus
- 10:30AM-12:30PM
-
Abstract Number: 2375
Can Damage Items Be Graded According to Severity in a Revised Organ Damage Index for Lupus?
- 10:30AM-12:30PM
-
Abstract Number: 2379
Causal Proteomics-Assisted Machine Learning Model Enhances Flare Risk Prediction in Systemic Lupus Erythematosus
- 10:30AM-12:30PM
-
Abstract Number: 2374
Characteristics, Treatment Responses and Prognosis in a Single Center Cohort of SLE Patients with Thrombocytopenia
- 10:30AM-12:30PM
-
Abstract Number: 2380
Characterizing SLE Patients into Type 1 and Type 2 Disease States: Insights from a Single Lupus Cohort
- 10:30AM-12:30PM
-
Abstract Number: 2415
Characterizing the Population with Suspected Lupus Nephritis in Care of a Community Rheumatology Network
- 10:30AM-12:30PM
-
Abstract Number: 2405
Chat-GPT Performance in Diagnosis of Rheumatological Diseases: A Comparison with Specialist’s Opinion
- 10:30AM-12:30PM
-
Abstract Number: 2389
Choroidal Thickness in Active Lupus Nephritis
- 10:30AM-12:30PM
-
Abstract Number: 2419
Clinical and Patient-reported Outcomes in Systemic Lupus Erythematosus: An Analysis of the SLE Prospective Observational Cohort Study (SPOCS) US Data
- 10:30AM-12:30PM
-
Abstract Number: 2392
Clinical Characteristics and Outcomes of Systemic Lupus Erythematosus When Accompanying Myositis: A Retrospective Real-Life Study
- 10:30AM-12:30PM
-
Abstract Number: 2381
Clinical Characteristics, Readmission Rates, and Outcomes in Lupus Patients with and Without Nephritic Involvement: Analysis from a National Database
- 10:30AM-12:30PM
-
Abstract Number: 2407
Clinical Utility of Repeat Renal Biopsies in Lupus Nephritis: The NIH Chronicity Index at First Biopsy Predicts Future End Stage Renal Disease in a Large South Asian Cohort of SLE
- 10:30AM-12:30PM
-
Abstract Number: 2393
Demographic Differences in Trends of Systemic Lupus Erythematosus In-hospital Patient Outcomes
- 10:30AM-12:30PM
-
Abstract Number: 2417
Frequency and Associated Factors of Herpes Zoster Infection in Systemic Lupus Erythematosus Patients from Latin-America
- 10:30AM-12:30PM
-
Abstract Number: 2403
Health-related Quality of Life in Women with Systemic Lupus Erythematosus with Permanent Skin Damage and Its Association with Self-esteem and Symptoms of Depression and Anxiety – a Cross-sectional Study
- 10:30AM-12:30PM
-
Abstract Number: 2418
Identification of Co-expressed Molecular Markers That Predict Risk of Severe Flare in Patients with Systemic Lupus Erythematosus (SLE)
- 10:30AM-12:30PM
-
Abstract Number: 2391
Identification of Patients with ANA Negative and Double Stranded DNA Positive: What Is the Significance in Daily Rheumatology Practise
- 10:30AM-12:30PM
-
Abstract Number: 2377
Impact of Neighborhood Area Deprivation Index on Outcomes in Lupus Patients in Bronx, NY
- 10:30AM-12:30PM
-
Abstract Number: 2408
Impact of Pain and Fatigue on Quality of Life Among Patients with Systemic Lupus Erythematosus
- 10:30AM-12:30PM
-
Abstract Number: 2372
Incidence and Predictors of Recurrent Pericarditis in Systemic Lupus Erythematosus
- 10:30AM-12:30PM
-
Abstract Number: 2397
Increase of IL10 and IFNa2 Are Associated to Clinical Activity in Systemic Lupus Erythematous Patients
- 10:30AM-12:30PM
-
Abstract Number: 2385
Increased Type I Interferon Inducible Genes Expression in the Peripheral Blood of Patients Presenting Cutaneous Lupus Erythematosus Manifestations
- 10:30AM-12:30PM
-
Abstract Number: 2378
Is Urinary Protein-creatinine Relation Reliable for Diagnosis or Follow up of Lupus Nephritis?
- 10:30AM-12:30PM
-
Abstract Number: 2386
Landscape of Immune Cells and Autoimmunity in Systemic Lupus Erythematosus Patients with Obesity
- 10:30AM-12:30PM
-
Abstract Number: 2404
Nailfold Dermoscopy: A Valuable Tool for Differentiating Dermatomyositis from Systemic Lupus Erythematosus
- 10:30AM-12:30PM
-
Abstract Number: 2399
Nationwide Analysis of Endovascular Thrombectomy in Ischemic Stroke Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis: Mortality and Healthcare Utilization
- 10:30AM-12:30PM
-
Abstract Number: 2406
Neuropsychiatric Manifestations in Indian SLE Inception Cohort for Research: Prevalence, Predictors and Outcomes
- 10:30AM-12:30PM
-
Abstract Number: 2383
Outcomes of Systemic Lupus Erythematosus Hospitalizations: Insights from a Multinational Tertiary Center Experience
- 10:30AM-12:30PM
-
Abstract Number: 2384
Performance and Concordance of Two Different Methods of Detecting the Commonest Autoantibodies in Systemic Lupus Erythematosus
- 10:30AM-12:30PM
-
Abstract Number: 2394
Perioperative Stress Dose vs Therapeutic Dose Comparison: One-Month Postoperative Outcomes in Moderate and Major Surgeries for Systemic Lupus Erythematous and Rheumatoid Arthritis
- 10:30AM-12:30PM
-
Abstract Number: 2400
Predicting Adverse Pregnancy Outcomes in Women with Systemic Lupus Erythematosus: External Validation of the PROMISSE Model Using Multiple Independent Cohorts
- 10:30AM-12:30PM
-
Abstract Number: 2396
PROMISing Outcomes: Understanding the Concordance Between Provider-assessment and Patient-reported Disease Activity in SLE
- 10:30AM-12:30PM
-
Abstract Number: 2388
Racial/Ethnic Variation in Multimorbidity Risk and Accrual and Comorbid Conditions Among Patients with Systemic Lupus Erythematosus
- 10:30AM-12:30PM
-
Abstract Number: 2370
Redefining Clinical Trial Inclusion Criteria Using Quality of Life in Cutaneous Lupus Erythematosus
- 10:30AM-12:30PM
-
Abstract Number: 2376
Systemic Lupus Erythematosus Patients Exhibit Dynamic Changes in Disease-Associated Transcripts Following Total Knee or Total Hip Arthroplasty
- 10:30AM-12:30PM
-
Abstract Number: 2373
The Construction and Validation of Sub-phenotype-specific Genetic Risk Scores in Systemic Lupus Erythematosus: A Novel Approach Using Large-scale Biobank Data
- 10:30AM-12:30PM
-
Abstract Number: 2416
The Impact of Active Lupus Nephritis on Work Productivity in Patients from a Latin American Lupus Cohort
- 10:30AM-12:30PM
-
Abstract Number: 2413
The Natural History of SLE Has Changed Since the 1970s
- 10:30AM-12:30PM
-
Abstract Number: 2398
The Relationship Between First-Trimester Maternal Serum 25-Hydroxyvitamin D and Maternal/Fetal Outcomes in Patients with Systemic Lupus Erythematosus
- 10:30AM-12:30PM
-
Abstract Number: 2371
The Role of Intracytoplasmic Toll- Like Receptors (TLR) and MyD88 in B Cell Subsets as Renal Response Predictors in Patients with Lupus Nephritis
- 10:30AM-12:30PM
-
Abstract Number: 2382
Utility of Urinary Biomarkers to Predict Long-term Renal Outcomes in Lupus Nephritis